## Summary

This paper proposes NF-BO, a latent Bayesian optimization method that replaces the VAE with an autoregressive normalizing flow (SeqFlow) to address the "value discrepancy problem" caused by imperfect VAE reconstruction. It also introduces a token-level adaptive candidate sampling strategy (TACS) for trust-region-based local search. Experiments on molecular optimization benchmarks (Guacamol, PMO) are presented.

## Strengths

- **Principled mathematical resolution of the value discrepancy problem**: Proposition 1 formally establishes that SeqFlow's invertible mapping guarantees perfect reconstruction of the discrete input from the latent representation. This provides a clean theoretical advantage over VAE-based LBO methods, where reconstruction is only approximate. The motivation for using normalizing flows over VAEs in this specific LBO setting is well-articulated.

- **TACS is well-motivated and mechanistically supported**: The token-level importance scoring via PMI is a principled way to bias candidate sampling toward important tokens. The diversity analysis (Section 6.1, Figure 6) provides concrete evidence that TACS increases candidate diversity, explaining *why* it improves search outcomes rather than just showing that it does.

- **Competitive benchmark results**: On the PMO benchmark (23 tasks, 25 baselines), the paper claims 1st rank on 5 of 6 metrics and that NF-BO improves VAE BO's average rank from 19th to 1st. While the supporting data is in an image, these claims — if substantiated — represent a substantial empirical achievement.

## Weaknesses

### Major

- **The baselines are never named.** Section 5.2 ("BASELINES") is completely empty — a section title with zero content. The paper later claims comparisons against "six LBO baselines" on Guacamol and "25 baseline models" on PMO but identifies none of them in the main text. Without knowing which methods were compared against and under what configurations, the empirical claims are fundamentally unverifiable. This is a basic reporting failure for an experimental paper.

- **The Guacamol evaluation is internally inconsistent and underspecified.** Section 5.1 states the method is tested on "seven challenging tasks" under "three different settings: (100, 500), (10,000, 10,000), and (10,000, 70,000)." Section 5.4 then reports results on "two Guacamol tasks" and "two experimental settings." Figure 5 only shows two settings. The paper never explains which two tasks were used, why the scope was reduced from seven to two, or what happened to the third setting. The reader cannot determine the actual scope of the evaluation.

- **The core claim is never tested in isolation.** The central thesis is that normalizing flows solve the value discrepancy problem caused by VAEs. However, the ablation (Figure 7) only compares NF-BO with vs. without TACS — testing the sampling strategy, not the flow. The paper never compares SeqFlow-based LBO against a matched VAE-based LBO with the same surrogate, acquisition function, and trust-region setup. Any performance improvement could come from the flow, the TACS sampling, the deep-kernel GP surrogate, or interactions among them. Without this controlled comparison, the paper's primary technical claim is methodologically untested.

### Minor

- **Key hyperparameters are unreported.** The number of flow blocks (K) and embedding dimension (F) are never given. TACS hyperparameters κ and τ are introduced with qualitative descriptions but no prescribed values or sensitivity analysis. This limits reproducibility and makes it impossible to assess how robust the method is to these choices.

- **Proposition 1's guarantee is slightly overstated.** The invertibility of g guarantees g^{-1}(g(e_x)) = e_x (perfect embedding reconstruction). However, the decoding step includes an argmax over cosine similarities to map the reconstructed embedding back to a token index. This argmax recovers the original token only if the embedding vectors of distinct tokens are sufficiently separated — a property encouraged by the similarity loss but not formally guaranteed. The paper presents the reconstruction as absolute without discussing this residual condition.

- **The "first to integrate normalizing flows into latent Bayesian optimization" claim** (stated in the abstract bullet and Section 2) is presented without any search scope or qualification. This bibliographic claim adds no technical value and should be softened or removed.

- **Numerical results are presented only as embedded images.** Table 1 and Figures 5–7 are graphs/images with no numerical values extractable from text. While the images are visible in the PDF, reporting key means and standard errors in text or a machine-readable table is standard practice for rigorous comparison.

### Trivial

None.

## Nice-to-Haves

- A controlled experiment comparing SeqFlow-based LBO against a matched VAE-based LBO (same surrogate, acquisition, trust region, candidate sampling) would directly test the core claim.
- Reporting molecular validity, novelty, and diversity alongside optimization scores would strengthen the molecular optimization evaluation.
- A discussion of the computational cost of SeqFlow relative to VAEs (training time, inference time, scaling with sequence length) would help practitioners assess the practical trade-offs.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **"Numerical results inaccessible making paper unreviewable"** (harsh critic Weakness 3): Demoted to Minor above. The images are visible in the PDF — the parser limitation does not make the paper unreviewable. The criticism was over-stated.
- **"Diversity analysis is redundant with ablation"** (harsh critic section notes): Removed. The diversity analysis provides mechanistic understanding of *why* TACS helps, which is distinct from the ablation showing *that* it helps. This is a strength, not a weakness.
- **"Deep kernel GP vs standard GP in baselines"** (harsh critic section notes): Removed. Since the baselines are never named (a separate weakness), we cannot determine what surrogates they use. This is speculation filling a gap created by the empty baselines section.
- **"No code or data release mentioned"** (harsh critic): Removed per hard rules — reproducibility concerns about unreleased artifacts are not valid criticisms of a submitted paper.
- **Generic/superficial strengths** (strength finder): Removed per rules. Claims about the problem being "important" or the paper "addressing an important challenge" are generic and carry no weight.

## Novel Insights

The one genuinely novel synthesis from the reviews is the identification that the paper's empirical evaluation contains a **structural asymmetry**: the TACS ablation (Figure 7) isolates one contribution, while the core claim (flow over VAE) has no counterpart ablation at all. This means the experimental section tests a secondary component but leaves the primary technical thesis unexamined by controlled comparison. This is not a minor oversight — it means the paper's headline findings could be driven entirely by the deep-kernel GP surrogate or by TACS, with SeqFlow contributing little. A reviewer looking for evidence of the central claim will find none in the current paper.

## Suggestions

1. Fill Section 5.2 with a proper table naming each baseline, providing citations, and describing the configuration used.
2. Resolve the Guacamol inconsistency: clearly state which tasks were used, why, and report all settings consistently.
3. Add a controlled ablation comparing SeqFlow-based LBO against a matched VAE-based LBO (same surrogate, acquisition, trust region, candidate sampling method) to directly test the core thesis.
4. Report K, F, κ, τ, and include a sensitivity analysis for the TACS hyperparameters.
5. Present key numerical results (means, standard errors) in text or a machine-readable table, not only in figures.
6. Soften the "first to integrate" bibliographic claim.

## Score and Decision

MY FINAL SCORE: <score>4</score>
MY FINAL DECISION: <decision>Reject</decision>